WO2004106519A3 - Mrp8/mrp14 inhibitors and the use thereof for preventing and/or treating hypertrophic scars and keloids - Google Patents

Mrp8/mrp14 inhibitors and the use thereof for preventing and/or treating hypertrophic scars and keloids Download PDF

Info

Publication number
WO2004106519A3
WO2004106519A3 PCT/EP2004/006012 EP2004006012W WO2004106519A3 WO 2004106519 A3 WO2004106519 A3 WO 2004106519A3 EP 2004006012 W EP2004006012 W EP 2004006012W WO 2004106519 A3 WO2004106519 A3 WO 2004106519A3
Authority
WO
WIPO (PCT)
Prior art keywords
mrp14
mrp8
inhibitors
keloids
preventing
Prior art date
Application number
PCT/EP2004/006012
Other languages
German (de)
French (fr)
Other versions
WO2004106519A2 (en
Inventor
Andreas Goppelt
Stephanie Fritz
Michaela Bittner
Original Assignee
Switch Biotech Ag
Andreas Goppelt
Stephanie Fritz
Michaela Bittner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Switch Biotech Ag, Andreas Goppelt, Stephanie Fritz, Michaela Bittner filed Critical Switch Biotech Ag
Publication of WO2004106519A2 publication Critical patent/WO2004106519A2/en
Publication of WO2004106519A3 publication Critical patent/WO2004106519A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to the use of Mrp8/Mrp14 inhibitors for producing a medicament for preventing and/or treating hypertrophic scars and keloids. The invention also relates to novel Mrp8 or Mrp14 inhibitors, particularly siRNA's.
PCT/EP2004/006012 2003-06-03 2004-06-03 Mrp8/mrp14 inhibitors and the use thereof for preventing and/or treating hypertrophic scars and keloids WO2004106519A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10324997.4 2003-06-03
DE10324997A DE10324997A1 (en) 2003-06-03 2003-06-03 Mrp8 / Mrp14 inhibitors and their use for the prevention and / or treatment of hypertrophic scars and keloids

Publications (2)

Publication Number Publication Date
WO2004106519A2 WO2004106519A2 (en) 2004-12-09
WO2004106519A3 true WO2004106519A3 (en) 2005-01-20

Family

ID=33482418

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/006012 WO2004106519A2 (en) 2003-06-03 2004-06-03 Mrp8/mrp14 inhibitors and the use thereof for preventing and/or treating hypertrophic scars and keloids

Country Status (2)

Country Link
DE (1) DE10324997A1 (en)
WO (1) WO2004106519A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5366077B2 (en) * 2007-02-09 2013-12-11 株式会社 資生堂 A skin disease model with inflammation and hyperproliferation
FR2941239B1 (en) * 2009-01-19 2013-11-15 Biomerieux Sa METHOD FOR DETERMINING THE SUSCEPTIBILITY TO CONTRACT NOSOCOMIAL INFECTION IN A PATIENT WITH AN INFLAMMATORY SYSTEMIC RESPONSE ASSOCIATED WITH OR NOT ASSOCIATED WITH INFECTION
KR20180026561A (en) 2009-01-19 2018-03-12 비오메리으 Methods for determining the likelihood of a patient contracting a nosocomial infection and for determining the prognosis of the course of a septic syndrome
NZ710495A (en) 2013-01-11 2019-10-25 Mark C Herzberg Therapeutic compositions and methods involving mrna transfection
CN104293789A (en) * 2014-10-14 2015-01-21 广西医科大学 siRNA for inhibiting gene expression of S100A8 and application thereof
CN104293788A (en) * 2014-10-14 2015-01-21 广西医科大学 SiRNA inhibiting expression of gene S100A9 and application of siRNA

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088181A2 (en) * 2001-04-30 2002-11-07 Switch Biotech Ag Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088181A2 (en) * 2001-04-30 2002-11-07 Switch Biotech Ag Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK NCBI; 12 September 1993 (1993-09-12), ODINK, K. ET AL.: "Human mRNA for calcium-binding protein in macrophages (MRP-14)", XP002299027, retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV Database accession no. X06233 *
DATABASE NUCLEOTIDE [online] NCBI; 12 September 1993 (1993-09-12), DORIN, J.R. ET AL.: "Human mrNA for cystic fibrosis antigen (CFAg)", XP002299028, Database accession no. Y00278 *
LI CONG ET AL: "Induction of S100A9 Gene Expression by Cytokine Oncostatin M in Breast Cancer Cells Through the STAT3 Signaling Cascade.", BREAST CANCER RESEARCH AND TREATMENT. SEP 2004, vol. 87, no. 2, September 2004 (2004-09-01), pages 123 - 134, XP002298482, ISSN: 0167-6806 *
THOREY IRMGARD S ET AL: "The Ca2+-binding proteins S100A8 and S100A9 are encoded by novel injury-regulated genes", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 38, 21 September 2001 (2001-09-21), pages 35818 - 35825, XP002298481, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
DE10324997A1 (en) 2004-12-23
WO2004106519A2 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
IL157652A (en) Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes
WO2004041269A3 (en) New use for pharmaceutical composition
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
WO2008057459A3 (en) Antagonists of pcsk9
WO2008057457A3 (en) Antagonists of pcsk9
EP1140840A4 (en) -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2004006858A3 (en) Compounds, compositions, and methods employing same
JO2373B1 (en) W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
EP1691842A4 (en) Treatment of proliferative diseases using an antisense iap oligomer and chemotherapeutic agent
WO2004080391A3 (en) Novel antibacterial agents
WO2005105829A3 (en) Caspase-2 inhibitors and their biological applications
WO2005044194A3 (en) TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
WO2004084932A3 (en) Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
WO2008078109A3 (en) Medicament
WO2005023191A3 (en) Rage-related methods and compositions for treating glomerular injury
WO2004106519A3 (en) Mrp8/mrp14 inhibitors and the use thereof for preventing and/or treating hypertrophic scars and keloids
TW200637542A (en) Lipase inhibitor, preventing and treating agent of skin disease
WO2004037168A3 (en) Treatment of pancreatitis with amylin
WO2003035048A3 (en) Methods for the treatment of osteoarthritis and compositions thereof
WO2001060343A3 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
AU2001280093A1 (en) Method for the prevention and treatment of retinopathy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: FESTSTELLUNG EINES RECHTSVERLUSTS NACH REGEL 69(1) EPUE (EPA FORM 1205A) VOM 10.02.2006

122 Ep: pct application non-entry in european phase